chronic obstructive pulmonary disease treatment (copd) market

The Lung Health Foundation Contracts with Cloud DX to Manage Chronic Obstructive Pulmonary Disease with Remote Patient Monitoring

Cloud DX (TSXV:CDX), a leading North American provider of virtual care and remote patient monitoring solutions announced today a new partnership with the Lung Health Foundation to supply remote patient monitoring (RPM) kits and services in the Province of Ontario. The Lung Health Foundation intends to deploy Cloud DX Connected Health through Ontario-based hospital partners to improve care for patients suffering from chronic obstructive pulmonary disease (COPD

This announcement is the latest in a series of contracts announced by Cloud DX in recent weeks, including a contract extension with a large Canadian provincial health authority, a partnership agreement with US-based Maxwell Telecare and a virtual clinic deployment in Newfoundland.

According to Canadian Institute of Health Information, over 23,000 Ontarians are admitted to hospital every year for COPD. Each hospital stay lasts an average of 5.6 days at an average cost to the province of $6,200 per visit or $142 million per year, making COPD exacerbation one of the largest healthcare costs in Ontario.

Cloud DX's remote patient monitoring platform is used by healthcare providers to improve COPD patient outcomes, with deployments at Markham Stouffville Hospital, Hamilton Health Sciences and Kingston Health Sciences Centre among others. Remote monitoring by Cloud DX helps clinicians detect symptoms of COPD exacerbation earlier, and trigger pre-approved action plans to guide COPD patients to take immediate steps to alleviate their symptoms, reducing ER visits and hospitalizations. The result is better healthcare outcomes for patients and lower COPD hospital costs.

This 12-month contract can be renewed by Lung Health or any of the participating healthcare partners at the completion of the initial term. Cloud DX charges upfront for Connected Health Kits that are prescribed to patients for use at home, and then charges a per patient per month fee for software, services and support as each patient enrolls in the Connected Health system. In this case, all fees are paid by Lung Health.

“The COVID-19 pandemic underscored the vulnerability of individuals with COPD. Remote patient monitoring has been shown to be beneficial in helping predict exacerbations while providing patients with critical information required to manage their own condition. Early intervention and better disease management improves quality of life and lowers healthcare resource utilization. Private-public partnerships such as the one between our two organizations are key to getting at the core of some of the healthcare challenges we've long been facing,” says Peter Glazier, Executive Vice President of the Lung Health Foundation.

"Cloud DX Connected Health has been shown to be a powerful tool to mitigate the impact of COPD, improving the lives of patients while at the same time streamlining provider workflows. We're proud to be a partner with the Lung Health Foundation to expand the number of Ontarians that have access to this life-changing technology," stated Cloud DX CEO Robert Kaul.

About the Lung Health Foundation

The Lung Health Foundation is the leading Canadian health charity dedicated to improving lung health through a uniquely integrated approach that identifies gaps and fills them through investments in ground-breaking research and urgently needed programs and supports, policy and practice change, and promoting awareness about lung health issues affecting all Canadians.

About Cloud DX

Accelerating virtual healthcare's future, Cloud DX is making healthcare better for everyone. The company's Connected Health remote patient monitoring platform is used by healthcare enterprises and care teams across North America to virtually manage chronic disease, enable ageing in place and deliver hospital-quality post-surgical care. Providers partnering with Cloud DX achieve better healthcare and patient outcomes, reduce the need for hospitalization/re-hospitalization and reduce the costs of healthcare delivery through more efficient use of resources. Cloud DX is the co-winner of the Qualcomm Tricorder XPRIZE, a 2021 Edison Award winner, a Fast Company “World Changing Idea” finalist and one of "Canada's Ten Most Prominent Telehealth Providers."

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Social Links

Twitter: https://twitter.com/CloudDX

Facebook https://www.facebook.com/clouddxinc/

LinkedIn https://www.linkedin.com/company/cloud-dx/

Instagram https://www.instagram.com/cloud.dx/

For media inquiries please contact:

Ellyn Winters-Robinson
Ignition Communications (PR for Cloud DX)
519-574-2196
ellyn@ignition.ca

For investor inquiries please contact:

Jay Bedard
Cloud DX Investor Relations
647-881-8418
jay.bedard@CloudDX.com

SOURCE:Cloud DX Inc.



View source version on accesswire.com:
https://www.accesswire.com/653436/The-Lung-Health-Foundation-Contracts-with-Cloud-DX-to-Manage-Chronic-Obstructive-Pulmonary-Disease-with-Remote-Patient-Monitoring

News Provided by ACCESSWIRE via QuoteMedia

The Conversation (0)
Sona Nanotech's THT Cancer Studies Demonstrates Strong Efficacy in Third Preclinical Study and Plans for First-in-human Early Feasibility Study

Sona Nanotech's THT Cancer Studies Demonstrates Strong Efficacy in Third Preclinical Study and Plans for First-in-human Early Feasibility Study

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") announces results from its most recent preclinical study of its Targeted Hyperthermia Therapy ("THT") which uses the Company's patented, biocompatible gold nanorods ("GNRs") to treat certain solid cancer tumors, shrinking them and acting as an immune stimulator. Building on its success in melanoma and breast cancer studies, the Company's third preclinical efficacy study was conducted in an immunologically 'cold' colorectal cancer model ("CT26"), a model that represents the majority of human colon cancers, which do not typically respond to current standard of care immunotherapies.

In this preliminary study, whereas no mice that were given standard immunotherapy alone showed any response, 100% of mice in the THT treatment group responded to the same immunotherapy with 50% (4 out of 8) of those tumors eliminated within 12 days of treatment, as shown by the green line in Figure 1, below.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Syntheia Announces Establishment of Advisory Board and Appointment of Travel Industry Expert, Mr. John Kirk

Syntheia Announces Establishment of Advisory Board and Appointment of Travel Industry Expert, Mr. John Kirk

Syntheia Corp. ("Syntheia" or the "Company") (Syntheia.ai), CSE SYAI, Syntheia, a Canadian leader in conversational AI SaaS, is pleased to announce the establishment of its new Advisory Board. The Advisory Board will collaborate with management and the board of directors to enhance the Company's strategic direction, provide expert guidance on its commercial initiatives, offer industry insights, and shape and accelerate innovations.

As the inaugural member of the Advisory Board, Syntheia welcomes Mr. John Kirk, a leader in the travel industry. The travel sector represents a potentially significant growth market for the Company's technology.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Syntheia Enhances Inbound Customer Calls with AI-Powered Virtual Assistants, Positively Impacts Sales and Customer Satisfaction

Syntheia Enhances Inbound Customer Calls with AI-Powered Virtual Assistants, Positively Impacts Sales and Customer Satisfaction

Syntheia Corp. ("Syntheia" or the "Company") (Syntheia.ai), CSE SYAI, Syntheia, a Canadian leader in conversational AI SaaS, is transforming customer service by delivering an innovative solution that uses natural language processing (NLP) to handle inbound telephone calls with virtual assistants. Since its beta launch in June 2023, Syntheia has processed over 750,000 conversations, bringing new levels of efficiency and engagement to businesses in diverse industries.

Companies like Georgetown Hyundai, Palmieri Furniture, Campio Furniture, and Pay N Go have all embraced Syntheia's platform, highlighting its positive impact on sales and customer satisfaction.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Zero Candida Technologies Inc.  Opens the Market

Zero Candida Technologies Inc. Opens the Market

Eli Ben-Haroosh, Co-Founder and Chief Executive Officer, Zero Candida Technologies Inc. (TSXV: ZCT) ("Zero Candida" or the "Company"), joined Dani Lipkin, Managing Director, Global Innovation Sector, Toronto Stock Exchange, to open the market to celebrate the Company's new listing on the TSX Venture Exchange.

Zero Candida Technologies, Inc. (ZCT), is a medical device company bringing female healthcare into the 21st century. They are transforming the treatment of Vulvo-Vaginal Candidiasis ("VVC"), which affects 75% of women worldwide, often recurrent and increasingly drug-resistant with current treatments failing to address the root cause effectively. Free from chemicals and side effects, their AI-driven tampon-like device enables real-time data collection and transmission to physicians for personalized, at-home treatment. Beyond VVC, ZCT aims to revolutionize gynecology, improving access for underserved populations and advancing hybrid medicine.

Please refer to the Company's website here.

MEDIA CONTACT:
Victoria Gamble
Corporate Development Consultant
victoria@zero-candida.com
416-706-0332

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/231280

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
XReality Group

xReality Group Limited Chairman’s Address 2024 Annual General Meeting – 22 November 2024

xReality Group Limited (ASX:XRG) (xReality) is pleased to present xReality Group Limited’s 2024 Annual General Meeting.

Keep reading...Show less
XReality Group

Operator XR – Sales Update November 24

xReality Group Limited (ASX:XRG) (xReality) is pleased to provide the following sales update for Operator XR, a wholly owned subsidiary of xReality Group Ltd. Operator XR provides Military and Law Enforcement agencies around the world with a unique, integrated Mission Planning & Rehearsal System, which is portable, secure, and highly immersive.

Keep reading...Show less

Latest Press Releases

Related News

×